tradmap

CLYM Earnings Climb Bio, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$4 -$2 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$74M -$37M $0 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-37% 23% 83% 0% 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$2 -$1 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$55M -$27M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-25% -12% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–21 of 21
Q2 20262026-06-30-0.382026-08-0610-Q
Q1 20262026-03-31-0.202026-05-0710-Q
FY 20252025-12-31-0.882026-03-0510-K
Q3 20252025-09-30-0.632025-11-0610-Q
Q2 20262025-06-30-0.442026-08-0610-Q
Q1 20262025-03-31-0.312026-05-0710-Q
FY 20252024-12-31-1.532026-03-0510-K
Q3 20252024-09-30-1.572025-11-0610-Q
Q2 20252024-06-30-1.952025-08-1210-Q
Q1 20252024-03-31-0.062025-05-1410-Q
FY 20242023-12-31-1.302025-03-2510-K
Q3 20242023-09-30-1.172024-11-1210-Q
Q2 20242023-06-30-1.032024-08-1410-Q
Q1 20242023-03-31-0.842024-05-1510-Q
FY 20232022-12-31-1.722024-03-2810-K
Q3 20232022-09-30-1.432023-11-1410-Q
Q3 20232022-06-30-1.432023-11-1410-Q
Q1 20232022-03-31-0.502023-05-1110-Q
FY 20222021-12-31-4.242023-03-0610-K
Q3 20222021-09-30-5.492022-11-1410-Q
Q2 20222021-06-30-8.802022-08-1510-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.